Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar 29:3:46.
doi: 10.3389/fendo.2012.00046. eCollection 2012.

Craniopharyngioma in adults

Affiliations

Craniopharyngioma in adults

Flavius Zoicas et al. Front Endocrinol (Lausanne). .

Abstract

Craniopharyngiomas are slow growing benign tumors of the sellar and parasellar region with an overall incidence rate of approximately 1.3 per million. During adulthood there is a peak incidence between 40 and 44 years. There are two histopathological types, the adamantinomatous and the papillary type. The later type occurs almost exclusively in adult patients. The presenting symptoms develop over years and display a wide spectrum comprising visual, endocrine, hypothalamic, neurological, and neuropsychological manifestations. Currently, the main treatment option consists in surgical excision followed by radiation therapy in case of residual tumor. Whether gross total or partial resection should be preferred has to be balanced on an individual basis considering the extent of the tumor (e.g., hypothalamic invasion). Although the overall long-term survival is good it is often associated with substantial morbidity. Preexisting disorders are often permanent or even exacerbated by treatment. Endocrine disturbances need careful replacement and metabolic sequelae should be effectively treated. Regular follow-up by a multidisciplinary team is a prerequisite for optimal outcome of these patients.

Keywords: adults; complications; craniopharyngioma; diagnosis; treatment.

PubMed Disclaimer

References

    1. Abs R., Bengtsson B. A., Hernberg-Stahl E., Monson J. P., Tauber J. P., Wilton P., Wuster C. (1999). GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin. Endocrinol. (Oxf.) 50, 703–71310.1046/j.1365-2265.1999.00695.x - DOI - PubMed
    1. Adamson T. E., Wiestler O. D., Kleihues P., Yasargil M. G. (1990). Correlation of clinical and pathological features in surgically treated craniopharyngiomas. J. Neurosurg. 73, 12–1710.3171/jns.1990.73.1.0012 - DOI - PubMed
    1. Barriger R. B., Chang A., Lo S. S., Timmerman R. D., DesRosiers C., Boaz J. C., Fakiris A. J. (2011). Phosphorus-32 therapy for cystic craniopharyngiomas. Radiother. Oncol. 98, 207–21210.1016/j.radonc.2010.12.001 - DOI - PubMed
    1. Bulow B., Attewell R., Hagmar L., Malmstrom P., Nordstrom C. H., Erfurth E. M. (1998). Postoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival, and tumor recurrence. J. Clin. Endocrinol. Metab. 83, 3897–390410.1210/jc.83.11.3897 - DOI - PubMed
    1. Bunin G. R., Surawicz T. S., Witman P. A., Preston-Martin S., Davis F., Bruner J. M. (1998). The descriptive epidemiology of craniopharyngioma. J. Neurosurg. 89, 547–55110.3171/jns.1998.89.4.0547 - DOI - PubMed

LinkOut - more resources